Bioxytran (BIXT) EPS (Basic) Growth (5y) (2016 - 2026)
Bioxytran (BIXT) EPS (Basic) Growth (5y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.90 Bn | 132.05 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.73 Bn | 60.55 Bn | 1.37 Bn |
| 4 | Moderna | 58.33 Bn | 53.19 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.72 Bn | 28.42 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.27 Bn | 9.88 Bn | 668.28 Mn |
| 8 | Insmed | 27.61 Bn | 26.45 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.25 Bn | 26.41 Bn | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.61% |
| Dec 31, 2025 | 7.98% |
| Sep 30, 2025 | -8.83% |
| Jun 30, 2025 | 15.34% |
| Mar 31, 2025 | -19.72% |
| Dec 31, 2024 | 6.86% |
| Sep 30, 2024 | 21.26% |
| Jun 30, 2024 | -19.60% |
| Mar 31, 2024 | -9.40% |
| Dec 31, 2023 | -24.49% |
| Sep 30, 2023 | -71.42% |
| Jun 30, 2023 | -436.42% |
| Mar 31, 2023 | -88.15% |
| Dec 31, 2022 | -28.01% |
| Sep 30, 2022 | -25.35% |
| Jun 30, 2022 | 6.89% |
| Mar 31, 2022 | -25.51% |
| Dec 31, 2021 | -31.31% |
| Sep 30, 2021 | 10.01% |
| Jun 30, 2021 | -9.82% |